Medifast stock faces a smaller coach base after Q2 revenue beat

Published on 10/07/2026 at 05:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medifast stock was last at USD 11.51 on October 6, 2026, while Q2 revenue reached USD 76.4 million. Coach productivity rose 41 percent year over year.

MED, US58470H1014, Illustration mit AI erstellt.

Medifast stock was last at USD 11.51 on the NYSE on October 6, 2026 at 4:00 p.m. ET, down 1.37 percent for the session. The latest operating picture combines a 27.6 percent year-over-year revenue decline with a 41 percent increase in average revenue per active earning coach.

Q2 revenue beat meets pressure

In its review of Medifast's second-quarter 2026 results, Zacks reported revenue of USD 76.4 million, compared with USD 105.6 million in the year-earlier quarter. The company posted a loss of USD 0.28 per share, narrower than the consensus loss of USD 0.67 per share.

The comparison is sharply mixed. Yahoo Finance reported that average revenue per active earning coach rose 41 percent year over year to USD 6,529, marking a third consecutive quarter of productivity growth. At the same time, the active earning coach base fell 48.7 percent year over year, leaving revenue under pressure despite better output per coach.

Guidance keeps losses in view

Management's third-quarter 2026 outlook calls for revenue of USD 60 million to USD 80 million and a loss of USD 0.15 to USD 0.65 per share, excluding one-time Catalyst cost-savings expenses, according to Zacks. Fiscal 2026 revenue guidance remains USD 270 million to USD 300 million, while the expected loss is USD 0.25 to USD 1.75 per share.

The operating tradeoff matters for investors. Higher productivity can support stabilization, but the 48.7 percent contraction in the coach base means Medifast still needs stronger recruitment and retention to convert productivity gains into revenue growth.

Consensus stays close to market price

MarketBeat reported on October 3, 2026 that two analysts rated Medifast Hold and one rated it Sell, producing a consensus rating of Reduce and an average price target of USD 12.00. That target lies 4.3 percent above the USD 11.51 last price.

Medifast's 52-week range was USD 9.22 to USD 14.15 on October 6, 2026. Market capitalization stood at USD 128.0 million, and trading volume reached 84,674 shares.

Medifast stock remains below yearly high

Medifast stock was last at USD 11.51 on the NYSE on October 6, 2026, placing it USD 2.64 below the 52-week high. The market is weighing improved coach productivity against the smaller coach network and continued fiscal-year losses.